

Cap.4 CRITERII PRIMARE DE PERFORMANTA

Anexa 4.1

4.1.1 Lista lucrărilor și citărilor, grupate pe ani (Ian 2005-Ian 2008)

Nr	Titlul lucrării	Autori	Revista
2007			
1	Clinical effects of erdosteine in the treatment of acute respiratory tract diseases in children	Balli F., Bergamini B., Calistru P. , Ciofu E.P., Domenici R., Doros G., Dragomir D., Gherghina I., Iordachescu F., Murgoci G., Orasanu D., Plesca D., Vaccaro A., Assereto R.	International Journal of Clinical Pharmacology and Therapeutics, Volume 45, Issue 1, January 2007, pages 16-22, <u>ISSN 0946-1965</u>

1 X30=30

Total punctaj 4.1.1= 30

4.1.2 Punctaj cumulată ISI

International Journal of Clinical Pharmacology and Therapeutics=0,69

Total ISI = 0,69

Total punctaj 4.1.2 =**0,69**

4.1.3. Număr de citări în reviste de specialitate cotate ISI¹

ANUL 2007			
Denumire Articol	Autori	Revista	Total citari 2005-2007
<u>Clinical effects of erdosteine in the treatment of acute respiratory tract diseases in children</u>	Balli, F., Bergamini, B., Calistru, P. , Ciofu, E.P., Domenici, R., Doros, G., Dragomir, D., Gherghina, I., Iordachescu, F., Murgoci, G., Orasanu, D., Plesca, D., Vaccaro, A., Assereto, R.	<u>International Journal of Clinical Pharmacology and Therapeutics</u> , Volume 45, Issue 1, January 2007, Pages 16-22	1
1. Effectiveness of erdosteine in elderly patients with bronchiectasis and hypersecretion: A 15-day, prospective, parallel, open-label, pilot study	<u>Crisafulli, E., Coletti, O., Costi, S., Zanasi, E., Lorenzi, C., Lucic, S., Fabbri, L.M., (...), Clini, E.M.</u>	<i>Clinical Therapeutics</i> 29 (9), pp. 2001-2009	2007
ANUL 2004			
<u>Allele frequencies of 13 short tandem repeat (STR)</u>	Barbarii, L.E., Rolf, B., Constantinescu,	<u>Forensic Science International</u>	9

¹ Sunt exclude autocitările.

<u>loci in the Romanian population</u>	C., Hohoff, C., <u>Calistru, P.</u> Dermengiu, D.	Volume 141, Issue 2-3, 10 May 2004, Pages 171-174	
1. Genetic STRs variation in a large population from Tuscany (Italy)	<u>Carboni, L., Nutini, A.L., Porfirio, B., Genuardi, M., Ricci, U.</u>	Forensic Science International: Genetics 1 (3-4), pp. e10-e11	2007
2. STR allele profile in forensic identification [Utilizarea profilului alelelor STR în identificarea originii persoanelor]	<u>Anghel, A., Marian, C., Samoila, C., Lenghel, F., Sfrijan, F.</u>	Romanian Journal of Legal Medicine 15 (3), pp. 234-236	2007
3. STR data for the 15 AmpFISTR identifier loci in the Western Romanian population	<u>Marian, C., Anghel, A., Bel, S.M., Ferencz, B.K., Ursoniu, S., Dressler, M., Popescu, O., Budowle, B.</u>	Forensic Science International 170 (1), pp. 73-75	2007
4. Population data on the 11 STR loci in the Upper Silesia (Poland)	<u>Raczek, E.</u>	Forensic Science International 168 (1), pp. 68-72	2007
5. Population genetic study in two Transylvanian populations using forensically informative autosomal and Y-chromosomal STR markers	<u>Egyed, B., Füredi, S., Padar, Z.</u>	Forensic Science International 164 (2-3), pp. 257-265	2006
6. Mutations or exclusion: An unusual case in paternity testing	<u>Junge, A., Brinkmann, B., Fimmers, R., Madea, B.</u>	International Journal of Legal Medicine 120 (6), pp. 360-363	2006
7. Analysis of the population heterogeneity in Hungary using fifteen forensically informative STR markers	<u>Egyed, B., Füredi, S., Angyal, M., Balogh, I., Kalmar, L., Padar, Z.</u>	Forensic Science International 158 (2-3), pp. 244-249	2006
8. Allele frequencies for 15 STR loci in a population from the Republic of Macedonia	<u>Jakovski, Z., Nikolova, K., Furac, I., Masic, M., Janeska, B., Kubat, M.</u>	International Journal of Legal Medicine 120 (1), pp. 53-55	2006
9. Population genetics of the d19s433 locus in the northern Poland	<u>Wysocka, J., Kapińska, E., Repała, K., Szczerkowska, Z., Cybulska, L.</u>	Annales Academiae Medicae Gedanensis 35, pp. 181-185	2005
ANUL 2003			
<u>Efficacy and safety of inhaled budesonide delivered once or twice daily via HFA-134a in mild to moderate persistent asthma in adult patients. Comparison with budesonide CFC</u>	Vastagh, E., Kuna, P., <u>Calistru, P.</u> , Bogdan, M.A.	<u>Respiratory Medicine</u> Volume 97, Issue SUPPL. D, November 2003, Pages S20-S28	8
1. Comparable long-term safety and efficacy of a novel budesonide/formoterol	Morice, A.H., Hochmuth, L., Ekelund, J., Thorén,	<i>Pulmonary Pharmacology and Therapeutics</i> Volume 21, Issue 1, February	2008

pressurized metered-dose inhaler versus budesonide/formoterol Turbuhaler® in adolescents and adults with asthma	A., Puterman, A.S.	2008, Pages 32-39	
2. Advances in asthma and COPD management: Delivering CFC-free inhaled therapy using Modulite® technology	<u>Acerbi, D.</u> , <u>Brambilla, G.</u> , <u>Kottakis, I.</u>	<i>Pulmonary Pharmacology and Therapeutics</i> 20 (3), pp. 290-303	2007
3. Short-term growth and adrenal function in children with asthma treated with inhaled beclomethasone dipropionate hydrofluoroalkane-134a	<u>Wolthers, O.D.</u>	<i>Pediatric Allergy and Immunology</i> 17 (8), pp. 613-619	2006
4. Systemic activity of inhaled hydrofluoroalkane-134a metered dose inhaler with beclomethasone dipropionate in children with asthma	<u>Wolthers, O.D.</u>	<i>Pediatric Asthma, Allergy and Immunology</i> 19 (3), pp. 172-179	2006
5. The greenhouse effect, Montreal Protocol and modern treatment of asthma - New types of inhalers - A systematic review and meta-analysis of randomised controlled trials about application of Modulite® technology in the treatment of asthma	<u>Macioch, T.</u> , <u>Winiarski, M.</u> , <u>Wardyn, K.A.</u>	<i>Family Medicine and Primary Care Review</i> 8 (3), pp. 994-996	2006
6. Modulite®: A simple solution to a difficult problem	<u>Lewis, D.A.</u> , <u>Ganderton, D.</u> , <u>Meakin, B.J.</u> , <u>Brambilla, G.</u>	<i>Family Medicine and Primary Care Review</i> 8 (3), pp. 994-996	2005
7. A randomized, double-blind, double-dummy, single-dose, crossover trial evaluating the efficacy and safety profiles of two dose levels (12 and 24 µg) of formoterol-HFA (pMDI) vs. those of a dose level (24 µg) of formoterol-DPI (Foradil®/Aerolizer™) and of placebo (pMDI or Aerolizer) in moderate to severe asthmatic patients	<u>Bousquet, J.</u> , <u>Guenolé, E.</u> , <u>Duvauchelle, T.</u> , <u>Vicaut, E.</u> , <u>Lefrançois, G.</u>	<i>Respiration</i> 72 (SUPPL. 1), pp. 3-5	2005
8. A randomized, double-blind, double-dummy, single-dose, crossover trial evaluating the efficacy and safety profiles of two dose levels (12 and 24 µg) of formoterol-HFA (pMDI) vs. those of a dose level (24 µg) of formoterol-DPI (Foradil®/Aerolizer™) and of	<u>Molimard, M.</u> , <u>Guenolé, E.</u> , <u>Duvauchelle, T.</u> , <u>Vicaut, E.</u> , <u>Lefrançois, G.</u>	<i>Respiration</i> 72 (SUPPL. 1), pp. 13-19	2005

placebo (pMDI or Aerolizer) in moderate to severe asthmatic patients			
<u>Clinical manifestations in the West Nile virus outbreak</u>	<u>Ceausu, E.,</u> Erscoiu, S., <u>Calistru, P.,</u> Ispas, D., Dorobat, O., Homos, M., Barbulescu, C., Cojocaru, I., Simion, C.V., Cristea, C., Oprea, C., Dumitrescu, C., Duiculescu, D., Marcu, I., Mociornița, C., Stoicev, T., Zolotușca, I., Calomfirescu, C., Rusu, R., Hodrea, R., Geamai, S., Paun, L.	Romanian Journal of Virology Volume 48, Issue 1-4, January 1997, Pages 3-11	11
1. Vaccination against mosquito borne viral infections: Current status	<u>Wiwanitkit, V.</u>	Iranian Journal of Immunology 4 (4), pp. 186-196	2007
2. The Stoichiometry of Antibody-Mediated Neutralization and Enhancement of West Nile Virus Infection	<u>Pierson, T.C., Xu, Q., Nelson, S., Oliphant, T., Nybakken, G.E., Fremont, DavedH., Diamond, M.S.</u>	Cell Host and Microbe 1 (2), pp. 135-145	2007
3. Caspase 3-dependent cell death of neurons contributes to the pathogenesis of West Nile virus encephalitis	<u>Samuel, M.A., Morrey, J.D., Diamond, M.S.</u>	Journal of Virology 81 (6), pp. 2614-2623	2007
4. Pathogenesis of West Nile virus infection: A balance between virulence, innate and adaptive immunity, and viral evasion	<u>Samuel, M.A., Diamond, M.S</u>	Journal of Virology 80 (19), pp. 9349-9360	2006
5. West Nile virus; ecology and epidemiology of an emerging pathogen in Colombia	<u>Berrocal, L., Peña, J., González, M., Mattar, S.</u>	Revista de Salud Publica 8 (2), pp. 218-228	2006
6. PKR and RNase L contribute to protection against lethal West Nile virus infection by controlling early viral spread in the periphery and replication in neurons	<u>Samuel, M.A., Whitby, K., Keller, B.C., Marri, A., Barchet, W., Williams, B.R.G., Silverman, R.H., (...), Diamond, M.S.</u>	Journal of Virology 80 (14), pp. 7009-7019	2006
7. West Nile virus: Epidemiology and clinical features of an emerging epidemic in the United States	<u>Hayes, E.B., Gubler, D.J.</u>	Annual Review of Medicine 57, pp. 181-194	2006
8. Skin manifestations of West Nile Virus infection	<u>Del Giudice, P., Schuffenecker, L., Zeller, H., Grelier,</u>	Dermatology 211 (4), pp. 348-350	2005

	<u>M., Vandebos, F., Dellamonica, P., Counillon, E.</u>		
9. Alpha/beta interferon protects against lethal West Nile virus infection by restricting cellular tropism and enhancing neuronal survival	<u>Samuel, M.A., Diamond, M.S.</u>	Journal of Virology 79 (21), pp. 13350-13361	2005
10. The emergence of West Nile virus during a large outbreak in Illinois in 2002	<u>Huhn, G.D., Austin, C., Langkop, C., Kelly, K., Lucht, R., Lampman, R., Novak, R., (...), Dworkin, M.S.</u>	American Journal of Tropical Medicine and Hygiene 72 (6), pp. 768-776	2005
11. West Nile Virus (WNV): Implication and generalities in blood transfusion	<u>Gallian, P., De Lamballerie, X., De Micco, P., Andreu, G.</u>	Transfusion Clinique et Biologique 12 (1), pp. 11-17	2005
TOTAL CITARI 2005-2007 = 29			

4.1.3. Numar de citari
Total punctaj cap. 4.1.3

29 x 5 = **145**
145 puncte

TOTAL PUNCTAJ CAP. 4: 175,69 puncte